# Box Inc: financial statements, quarterly

BOX · NYSE · CIK 1372612 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/box.md) · [Financials](/companies/box/financials.md) · [Filings](/companies/box/filings.md) · [Insiders](/companies/box/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/box/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [262](/filings/0000950170-24-133239.md) | [263 d](/filings/0001193125-26-098466.md) | [265](/filings/0000950170-25-078934.md) | [270](/filings/0000950170-25-111701.md) | [276](/filings/0001193125-25-306665.md) | [280 d](/filings/0001193125-26-098466.md) | [276](/filings/0001193125-26-241872.md) | [294](/filings/0001193125-26-368289.md) | [301](/filings/0001193125-25-306665.md) | [306 d](/filings/0001193125-26-098466.md) | [306](/filings/0001193125-26-241872.md) | [321](/filings/0001193125-26-368289.md) |
| Cost of revenue | $m | [69.2](/filings/0000950170-24-133239.md) | [62.7 d](/filings/0001193125-26-098466.md) | [58.3](/filings/0000950170-25-078934.md) | [55.5](/filings/0000950170-25-111701.md) | [55.6](/filings/0001193125-25-306665.md) | [58.8 d](/filings/0001193125-26-098466.md) | [60.7](/filings/0001193125-26-241872.md) | [61.5](/filings/0001193125-26-368289.md) | [61.6](/filings/0001193125-25-306665.md) | [60.9 d](/filings/0001193125-26-098466.md) | [62.7](/filings/0001193125-26-241872.md) | [67.2](/filings/0001193125-26-368289.md) |
| Gross profit | $m | [192](/filings/0000950170-24-133239.md) | [200 d](/filings/0001193125-26-098466.md) | [206](/filings/0000950170-25-078934.md) | [215](/filings/0000950170-25-111701.md) | [220](/filings/0001193125-25-306665.md) | [221 d](/filings/0001193125-26-098466.md) | [216](/filings/0001193125-26-241872.md) | [232](/filings/0001193125-26-368289.md) | [240](/filings/0001193125-25-306665.md) | [245 d](/filings/0001193125-26-098466.md) | [243](/filings/0001193125-26-241872.md) | [254](/filings/0001193125-26-368289.md) |
| Research and development | $m | [61.0](/filings/0000950170-24-133239.md) | [61.9 d](/filings/0001193125-26-098466.md) | [62.7](/filings/0000950170-25-078934.md) | [65.4](/filings/0000950170-25-111701.md) | [67.9](/filings/0001193125-25-306665.md) | [68.9 d](/filings/0001193125-26-098466.md) | [72.3](/filings/0001193125-26-241872.md) | [71.7](/filings/0001193125-26-368289.md) | [73.9](/filings/0001193125-25-306665.md) | [76.6 d](/filings/0001193125-26-098466.md) | [75.9](/filings/0001193125-26-241872.md) | [78.4](/filings/0001193125-26-368289.md) |
| Operating income | $m | [11.4](/filings/0000950170-24-133239.md) | [21.2 d](/filings/0001193125-26-098466.md) | [18.0](/filings/0000950170-25-078934.md) | [20.3](/filings/0000950170-25-111701.md) | [23.4](/filings/0001193125-25-306665.md) | [17.9 d](/filings/0001193125-26-098466.md) | [6.3](/filings/0001193125-26-241872.md) | [20.6](/filings/0001193125-26-368289.md) | [25.1](/filings/0001193125-25-306665.md) | [31.2 d](/filings/0001193125-26-098466.md) | [27.4](/filings/0001193125-26-241872.md) | [32.6](/filings/0001193125-26-368289.md) |
| Interest expense | $m | not reported | not reported | [0.8](/filings/0000950170-25-078934.md) | [0.8](/filings/0000950170-25-111701.md) | [1.6](/filings/0001193125-25-306665.md) | [2.9 d](/filings/0001193125-26-098466.md) | [2.7](/filings/0001193125-26-241872.md) | [2.7](/filings/0001193125-26-368289.md) | [2.7](/filings/0001193125-25-306665.md) | [2.6 d](/filings/0001193125-26-098466.md) | [2.4](/filings/0001193125-26-241872.md) | [2.4](/filings/0001193125-26-368289.md) |
| Income tax | $m | [2.5](/filings/0000950170-24-133239.md) | [(73.7) d](/filings/0001193125-26-098466.md) | [4.6](/filings/0000950170-25-078934.md) | [4.5](/filings/0000950170-25-111701.md) | [4.4](/filings/0001193125-25-306665.md) | [(173) d](/filings/0001193125-26-098466.md) | [5.0](/filings/0001193125-26-241872.md) | [10.3](/filings/0001193125-26-368289.md) | [15.3](/filings/0001193125-25-306665.md) | [(47.2) d](/filings/0001193125-26-098466.md) | [9.8](/filings/0001193125-26-241872.md) | [12.6](/filings/0001193125-26-368289.md) |
| Net income | $m | [10.7](/filings/0000950170-24-133239.md) | [99.2 d](/filings/0001193125-26-098466.md) | [17.2](/filings/0000950170-25-078934.md) | [20.5](/filings/0000950170-25-111701.md) | [12.9](/filings/0001193125-25-306665.md) | [194 d](/filings/0001193125-26-098466.md) | [8.2](/filings/0001193125-26-241872.md) | [13.4](/filings/0001193125-26-368289.md) | [12.1](/filings/0001193125-25-306665.md) | [81.7 d](/filings/0001193125-26-098466.md) | [17.7](/filings/0001193125-26-241872.md) | [19.2](/filings/0001193125-26-368289.md) |
| Diluted EPS | $ per share | [0.04](/filings/0000950170-24-133239.md) | not reported | [0.08](/filings/0000950170-25-078934.md) | [0.10](/filings/0000950170-25-111701.md) | [0.05](/filings/0001193125-25-306665.md) | not reported | [0.02](/filings/0001193125-26-241872.md) | [0.05](/filings/0001193125-26-368289.md) | [0.05](/filings/0001193125-25-306665.md) | not reported | [0.08](/filings/0001193125-26-241872.md) | [0.09](/filings/0001193125-26-368289.md) |
| Basic EPS | $ per share | [0.04](/filings/0000950170-24-133239.md) | not reported | [0.08](/filings/0000950170-25-078934.md) | [0.10](/filings/0000950170-25-111701.md) | [0.05](/filings/0001193125-25-306665.md) | not reported | [0.02](/filings/0001193125-26-241872.md) | [0.06](/filings/0001193125-26-368289.md) | [0.05](/filings/0001193125-25-306665.md) | not reported | [0.09](/filings/0001193125-26-241872.md) | [0.10](/filings/0001193125-26-368289.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [378](/filings/0000950170-23-068562.md) | [384](/filings/0000950170-25-036261.md) | [450](/filings/0000950170-24-066563.md) | [407](/filings/0000950170-24-102328.md) | [609](/filings/0000950170-24-133239.md) | [625](/filings/0001193125-26-098466.md) | [690](/filings/0000950170-25-078934.md) | [658](/filings/0000950170-25-111701.md) | [633](/filings/0001193125-25-306665.md) | [375](/filings/0001193125-26-368289.md) | [379](/filings/0001193125-26-241872.md) | [343](/filings/0001193125-26-368289.md) |
| Current assets | $m | [684](/filings/0000950170-23-068562.md) | [842](/filings/0000950170-25-036261.md) | [789](/filings/0000950170-24-066563.md) | [734](/filings/0000950170-24-102328.md) | [963](/filings/0000950170-24-133239.md) | [1,098](/filings/0001193125-26-098466.md) | [1,056](/filings/0000950170-25-078934.md) | [1,043](/filings/0000950170-25-111701.md) | [1,024](/filings/0001193125-25-306665.md) | [891](/filings/0001193125-26-368289.md) | [766](/filings/0001193125-26-241872.md) | [758](/filings/0001193125-26-368289.md) |
| Total assets | $m | [1,034](/filings/0000950170-23-068562.md) | [1,241](/filings/0000950170-25-036261.md) | [1,176](/filings/0000950170-24-066563.md) | [1,121](/filings/0000950170-24-102328.md) | [1,354](/filings/0000950170-24-133239.md) | [1,668](/filings/0001193125-26-098466.md) | [1,641](/filings/0000950170-25-078934.md) | [1,625](/filings/0000950170-25-111701.md) | [1,609](/filings/0001193125-25-306665.md) | [1,546](/filings/0001193125-26-368289.md) | [1,422](/filings/0001193125-26-241872.md) | [1,404](/filings/0001193125-26-368289.md) |
| Current liabilities | $m | [571](/filings/0000950170-23-068562.md) | [679](/filings/0000950170-25-036261.md) | [591](/filings/0000950170-24-066563.md) | [587](/filings/0000950170-24-102328.md) | [587](/filings/0000950170-24-133239.md) | [922](/filings/0001193125-26-098466.md) | [877](/filings/0000950170-25-078934.md) | [853](/filings/0000950170-25-111701.md) | [853](/filings/0001193125-25-306665.md) | [803](/filings/0001193125-26-368289.md) | [717](/filings/0001193125-26-241872.md) | [716](/filings/0001193125-26-368289.md) |
| Total liabilities | $m | [1,083](/filings/0000950170-23-068562.md) | [1,180](/filings/0000950170-25-036261.md) | [1,081](/filings/0000950170-24-066563.md) | [1,067](/filings/0000950170-24-102328.md) | [1,341](/filings/0000950170-24-133239.md) | [1,470](/filings/0001193125-26-098466.md) | [1,427](/filings/0000950170-25-078934.md) | [1,399](/filings/0000950170-25-111701.md) | [1,400](/filings/0001193125-25-306665.md) | [1,349](/filings/0001193125-26-368289.md) | [1,263](/filings/0001193125-26-241872.md) | [1,258](/filings/0001193125-26-368289.md) |
| Long-term debt | $m | [370](/filings/0000950170-23-068562.md) | [371](/filings/0000950170-25-036261.md) | [371](/filings/0000950170-24-066563.md) | [372](/filings/0000950170-24-102328.md) | [652](/filings/0000950170-24-133239.md) | [449](/filings/0001193125-26-098466.md) | [449](/filings/0000950170-25-078934.md) | [450](/filings/0000950170-25-111701.md) | [450](/filings/0001193125-25-306665.md) | [451](/filings/0001193125-26-368289.md) | [452](/filings/0001193125-26-241872.md) | [452](/filings/0001193125-26-368289.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0000950170-25-036261.md) | not reported | not reported | not reported | [204](/filings/0001193125-26-098466.md) | [204](/filings/0000950170-25-078934.md) | [204](/filings/0000950170-25-111701.md) | [205](/filings/0001193125-25-306665.md) | [0.0](/filings/0001193125-26-098466.md) | not reported | not reported |
| Shareholders' equity | $m | [(540)](/filings/0000950170-24-133239.md) | [(431)](/filings/0001193125-26-098466.md) | [(398)](/filings/0000950170-25-111701.md) | [(439)](/filings/0001193125-25-306665.md) | [(480)](/filings/0001193125-25-306665.md) | [(297)](/filings/0001193125-26-368289.md) | [(280)](/filings/0001193125-26-368289.md) | [(269)](/filings/0001193125-26-368289.md) | [(287)](/filings/0001193125-25-306665.md) | [(299)](/filings/0001193125-26-368289.md) | [(338)](/filings/0001193125-26-368289.md) | [(351)](/filings/0001193125-26-368289.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [71.8 d](/filings/0000950170-24-133239.md) | [89.3 d](/filings/0001193125-26-098466.md) | [131](/filings/0000950170-25-078934.md) | [36.3 d](/filings/0000950170-25-111701.md) | [62.6 d](/filings/0001193125-25-306665.md) | [102 d](/filings/0001193125-26-098466.md) | [127](/filings/0001193125-26-241872.md) | [46.0 d](/filings/0001193125-26-368289.md) | [73.0 d](/filings/0001193125-25-306665.md) | [110 d](/filings/0001193125-26-098466.md) | [140](/filings/0001193125-26-241872.md) | [70.8 d](/filings/0001193125-26-368289.md) |
| Capital expenditure | $m | [2.5 d](/filings/0000950170-24-133239.md) | [0.2 d](/filings/0001193125-26-098466.md) | [1.3](/filings/0000950170-25-078934.md) | [0.4 d](/filings/0000950170-25-111701.md) | [0.3 d](/filings/0001193125-25-306665.md) | [0.6 d](/filings/0001193125-26-098466.md) | [0.3](/filings/0001193125-26-241872.md) | [1.9 d](/filings/0001193125-26-368289.md) | [2.0 d](/filings/0001193125-25-306665.md) | [1.9 d](/filings/0001193125-26-098466.md) | [1.3](/filings/0001193125-26-241872.md) | [0.1 d](/filings/0001193125-26-368289.md) |
| Share repurchases | $m | [51.0 d](/filings/0000950170-24-133239.md) | [21.2 d](/filings/0001193125-26-098466.md) | [32.1](/filings/0000950170-25-078934.md) | [107 d](/filings/0000950170-25-111701.md) | [30.0 d](/filings/0001193125-25-306665.md) | [42.4 d](/filings/0001193125-26-098466.md) | [49.7](/filings/0001193125-26-241872.md) | [39.9 d](/filings/0001193125-26-368289.md) | [76.9 d](/filings/0001193125-25-306665.md) | [123 d](/filings/0001193125-26-098466.md) | [116](/filings/0001193125-26-241872.md) | [69.3 d](/filings/0001193125-26-368289.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [148](/filings/0000950170-23-068562.md) | [150](/filings/0000950170-24-066563.md) | [150](/filings/0000950170-24-102328.md) | [148](/filings/0000950170-24-133239.md) | [149](/filings/0000950170-25-078934.md) | [147](/filings/0000950170-25-111701.md) | [149](/filings/0001193125-25-306665.md) | [150](/filings/0001193125-26-241872.md) | [151](/filings/0001193125-26-368289.md) | [149](/filings/0001193125-25-306665.md) | [140](/filings/0001193125-26-241872.md) | [140](/filings/0001193125-26-368289.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 137,200,773 at 2026-07-31, from the cover of the [10-Q filed 2026-08-26](/filings/0001193125-26-368289.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.